Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state

被引:51
作者
Kim, Mikyung
Qiao, Zhisong
Yu, Jessica
Montefiori, David
Reinherz, Ellis L.
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Lab Immunobiol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
[3] Duke Univ, Ctr Med, Dept Surg, Durham, NC 27710 USA
关键词
HIV; gp41; MPER; immunogen; immunodominance; neutralizing antibody; 2F5; 4E10; virus-like particle; vaccine;
D O I
10.1016/j.vaccine.2006.09.071
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The conserved membrane proximal external region (MPER) of the ectodomain of human immunodeficiency virus type I (HIV-1) gp41 is the target of two broadly neutralizing antibodies, 2F5 and 4E10. However, no neutralizing antibodies have been elicited against immunogens bearing these epitopes. Given that structural and biochemical studies suggest that the lipid membrane of the virion is involved in their proper configuration, HIV-1 gp41 derivatives in a pre-fusion state were expressed on the surface of immature virus like particles (VLP) derived from Sf9 cells. Guinea pigs were immunized with three doses of VLPs or Sf9 cells presenting gp41 derivatives with or without E. coli heat-labile enterotoxin (LT) as an adjuvant. While immune sera contained high titer anti-VLP antibodies, the specific anti-gp41 antibody responses were low with no neutralizing antibodies detected. An explanation for this absence may be the low level of gp41 expression relative to the many other proteins derived from host cells which are incorporated onto the VLP surface. In addition, the anti-gp41 immune response was preferentially directed to the C-helical domain, away from the MPER. Future vaccine design needs to contend with the complexity of epitope display as well as immunodominance. (C) 2006 Elsevier Ltd. All fights reserved.
引用
收藏
页码:5102 / 5114
页数:13
相关论文
共 87 条
  • [41] Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein
    Liang, XP
    Munshi, S
    Shendure, J
    Mark, G
    Davies, ME
    Freed, DC
    Montefiori, DC
    Shiver, JW
    [J]. VACCINE, 1999, 17 (22) : 2862 - 2872
  • [42] Induction of high level of specific antibody response to the neutralizing epitope ELDKWA on HIV-1 gp41 by peptide-vaccine
    Liao, MF
    Lu, Y
    Xiao, Y
    Dierich, MP
    Chen, YH
    [J]. PEPTIDES, 2000, 21 (04) : 463 - 468
  • [43] HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity
    Louder, MK
    Sambor, A
    Chertova, E
    Hunte, T
    Barrett, S
    Ojong, F
    Sanders-Buell, E
    Zolla-Pazner, S
    McCutchan, FE
    Roser, JD
    Gabuzda, D
    Lifson, JD
    Mascola, JR
    [J]. VIROLOGY, 2005, 339 (02) : 226 - 238
  • [44] Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment
    Luo, M
    Yuan, F
    Liu, YX
    Jiang, SM
    Song, XJ
    Jiang, PF
    Yin, XL
    Ding, MX
    Deng, HK
    [J]. VACCINE, 2006, 24 (04) : 435 - 442
  • [45] Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations
    Mackay, F
    Woodcock, SA
    Lawton, P
    Ambrose, C
    Baetscher, M
    Schneider, P
    Tschopp, J
    Browning, JL
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (11) : 1697 - 1710
  • [46] BAFF: A fundamental survival factor for B cells
    Mackay, F
    Browning, JL
    [J]. NATURE REVIEWS IMMUNOLOGY, 2002, 2 (07) : 465 - 475
  • [47] Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
    Mascola, JR
    Lewis, MG
    Stiegler, G
    Harris, D
    VanCott, TC
    Hayes, D
    Louder, MK
    Brown, CR
    Sapan, CV
    Frankel, SS
    Lu, YC
    Robb, ML
    Katinger, H
    Birx, DL
    [J]. JOURNAL OF VIROLOGY, 1999, 73 (05) : 4009 - 4018
  • [48] Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
    Mascola, JR
    Stiegler, G
    VanCott, TC
    Katinger, H
    Carpenter, CB
    Hanson, CE
    Beary, H
    Hayes, D
    Frankel, SS
    Birx, DL
    Lewis, MG
    [J]. NATURE MEDICINE, 2000, 6 (02) : 207 - 210
  • [49] HIV-1 vaccine development: Constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb
    McGaughey, GB
    Citron, M
    Danzeisen, RC
    Freidinger, RM
    Garsky, VM
    Hurni, WM
    Joyce, JG
    Liang, X
    Miller, M
    Shiver, J
    Bogusky, MJ
    [J]. BIOCHEMISTRY, 2003, 42 (11) : 3214 - 3223
  • [50] Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10
    Mehandru, S
    Wrin, T
    Galovich, J
    Stiegler, G
    Vcelar, B
    Hurley, A
    Hogan, C
    Vasan, S
    Katinger, H
    Petropoulos, CJ
    Markowitz, M
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (24) : 14039 - 14042